

Fax cover sheet

To: _____

Fax number: _____

Date/time: _____

From: _____

Fax number: _____

Number of pages (including this one): _____

Comments:

REQUIRED DOCUMENTATION

- ☐ 1) Complete patient enrollment
- ☐ 2) Document PAH diagnosis
- ☐ 3) Determine PAH clinical status
- ☐ 4) Complete CCB trial
- ☐ 5) Provide required documentation: right heart catheterization, echocardiogram results, and history and physical notes

Reminder: Please include photocopy of both sides of patient insurance card.

Fax completed forms to your patient's specialty pharmacy:

Accredo Health Group

Fax: 1-800-711-3526

Phone: 1-866-344-4874

CVS/specialty

Fax: 1-877-943-1000

Phone: 1-877-242-2738

Submission of the VELETRI® enrollment form is not a guarantee of patient approval. Additional testing and clinical information may be requested in some cases, including:

- Antinuclear antibody results
- Pulmonary function tests
- V/Q perfusion scan
- Chest CT

1

VELETRI® (EPOPROSTENOL) FOR INJECTION FORM**Complete patient prescription and enrollment form****Fax to your patient's specialty pharmacy:****Accredo Health Group****Fax: 1-800-711-3526****CVS/specialty****Fax: 1-877-943-1000****Referral date:** _____ ☐ **New patient** ☐ **Current**

| | | | | |
|---------------------|--|------------|---|--|
| Prescription | VELETRI®—continuous IV infusion administered via ambulatory pump Dosing weight: _____ <input type="checkbox"/> lbs <input type="checkbox"/> kg Height: _____ <input type="checkbox"/> in <input type="checkbox"/> cm <input type="checkbox"/> NKDA <input type="checkbox"/> Known drug allergies: _____ Diabetic: <input type="checkbox"/> Yes <input type="checkbox"/> No Initial dose: _____ ng per kg per min Titrate by _____ ng per kg per min every _____ days until goal of _____ ng per kg per min is reached. Discharge dose: _____ ng per kg per min Concentration: _____ ng/mL Dispense two (2) ambulatory infusion pumps appropriate for VELETRI® if the patient does not currently have appropriate ambulatory infusion pumps. Refills: 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5 <input type="checkbox"/> 6 <input type="checkbox"/> 7 <input type="checkbox"/> 8 <input type="checkbox"/> 9 <input type="checkbox"/> 10 <input type="checkbox"/> 11 <input type="checkbox"/> Patients should keep at least a 7-day backup supply of medicine and supplies at all times. | | Ship-to directions: <input type="checkbox"/> Physician's office <input type="checkbox"/> Patient's home <input type="checkbox"/> Hospital | |
| | Address (no PO Box): _____ | | City: _____ | |
| | State: _____ | ZIP: _____ | Ship Attn: _____ | |
| | Quantity: Dispense 1 month of drug and supplies, including pump(s) Choose one: <input type="checkbox"/> Sterile water for injection <input type="checkbox"/> Sodium chloride 0.9% injection | | | |
| | I certify that I am prescribing VELETRI® for this patient as a medically appropriate treatment. Prescriber's Signature _____ Prescriber's printed name: _____ Date: _____ <small>(Physician attests this is his/her legal signature. NO STAMPS) This prescription is valid only if transmitted by means of a facsimile machine.</small> | | | |

Choose one: ☐ Urgent: Patient in hospital ☐ Emergent: Admission after 48-72 hours ☐ Standard: Admission within 4+ days**Start-of-care date** (REQUIRED): _____ **Tentative discharge date:** _____**Nursing services** requested to be provided by the specialty pharmacy staff (Check all that apply):☐ In-hospital training ☐ Postdischarge visit/in-home follow-up ☐ Home assessment/training prior to initiation of therapy ☐ Dispense teaching kits☐ **DECLINE:** All referenced nursing*If nursing services will be required for therapy administration, the home health nurse will call for additional orders per state regulations.*

Discharge planner/coordinator name _____

Date: _____ Time: _____ Fax #: _____ Office/page phone #: _____

REQUIRED: PLEASE PROVIDE COPIES OF PATIENT'S CURRENT MEDICAL INSURANCE AND PRESCRIPTION CARDS.

| | | | | |
|------------------------------|---|--------|---|--------------------|
| Physician Information | All fields must be completed to expedite prescription fulfillment. | | | |
| | Name: | | DEA # (optional): | NPI #: |
| | Name of facility: | | MD specialty: | UPIN #: |
| | Contact name and phone #: | | State license #: | Phone #: |
| | Address: | Suite: | City: | State: ZIP: Fax #: |
| | Referral source: (check one) <input type="checkbox"/> Prescribing physician <input type="checkbox"/> Patient self-referral <input type="checkbox"/> No referring MD | | PCP (if applicable/different from prescribing MD): _____ Phone #: _____ | |

| | | | | |
|----------------------------|--|--|----------|--|
| Patient Information | Name: | | | DOB: |
| | Address: | | City: | State: ZIP: |
| | Preferred language, if not English: | | Phone #: | Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female |
| | Parent/guardian (if applicable): | | | Alternate phone #: |
| | May we contact the patient regarding insurance benefits and product delivery? <input type="checkbox"/> Yes <input type="checkbox"/> No | | | |

| | | | | |
|------------------------------|------------------------------|--|----------|-----------------|
| Insurance Information | Primary insurance company: | | | Phone #: |
| | Policy holder name: | | | DOB: |
| | Relationship to patient: | | ID #: | Group/policy #: |
| | Secondary insurance company: | | | Phone #: |
| | Policy holder name: | | | DOB: |
| | Relationship to patient: | | ID #: | Group/policy #: |
| | Drug card company: | | Phone #: | ID #: |
| | Rx BIN #: | | PCN #: | Person code: |

2

Document diagnosis

Fax to your patient's specialty pharmacy:

Accredo Health Group

Fax: 1-800-711-3526

CVS/specialty

Fax: 1-877-943-1000

Patient: _____ DOB: _____

Physician: _____

It is the responsibility of the Prescriber to complete this form with information that most accurately and completely describes the condition of the patient, regardless of the potential impact on insurance coverage or reimbursement. Johnson & Johnson makes no representation that the diagnosis information printed on this form is accurate or complete or that it will support insurance coverage or reimbursement.

Please select the diagnosis information that most accurately and completely describes the signs, symptoms, and condition of the patient:

DIAGNOSIS—THE FOLLOWING ICD-10 CODES DO NOT SUGGEST APPROVAL, COVERAGE, OR REIMBURSEMENT FOR SPECIFIC USES OR INDICATIONS. (CHECK THE BOX FOR THE APPROPRIATE CODE BELOW.)

- ☐ ICD-10 I27.0 Primary pulmonary hypertension
- ☐ ICD-10 I27.21 Secondary pulmonary arterial hypertension
- ☐ Other: _____

MEDICAL RATIONALE FOR OTHER

Prescriber signature: _____ Date: _____

3

Determine clinical status

Fax to your patient's specialty pharmacy:

Accredo Health Group

Fax: 1-800-711-3526

CVS/specialty

Fax: 1-877-943-1000

Patient: _____ DOB: _____

Physician: _____

NYHA functional class: (Check only one)

- ☐ Class III
- ☐ Class IV
- ☐ Other: _____

Clinical signs and symptoms: (Check all appropriate)

- ☐ Fatigue
- ☐ Shortness of breath or dyspnea on exertion
- ☐ 6-minute walk distance: _____ meters Date of evaluation: _____
- ☐ Chest pain or pressure (angina)
- ☐ Syncope or near syncope
- ☐ Edema or fluid retention
- ☐ Increasing limitation of physical activity
- ☐ Other: _____

Course of illness: (Check all appropriate)

- ☐ Evidence of worsening heart failure (eg, rales on physical exam, worsening edema, increased NT-proBNP, increased CRP)
- ☐ Worsening pulmonary hemodynamics (eg, mPAP, RAP, PVR, CO)
- ☐ Decreasing 6-minute walk test
- ☐ Change in functional class
- ☐ Worsening dyspnea on exertion
- ☐ Change in patient-reported symptoms (eg, increased fatigue)
- ☐ Other: _____

Prescriber signature: _____ **Date:** _____

4

Complete calcium channel blocker trial

Fax to your patient's specialty pharmacy:

Accredo Health Group

Fax: 1-800-711-3526

CVS/specialty

Fax: 1-877-943-1000

Patient: _____ DOB: _____

Physician: _____

Prior to the initiation of VELETRI® (epoprostenol) for Injection, Medicare policy requires documentation that a calcium channel blocker (CCB) has been tried, failed, or considered and ruled out.

The above named patient was trialed as follows:

☐ **A CCB was not trialed because:**

- ☐ Patient did not meet ACCP Guidelines for Vasodilator Response (ie, a fall in mPAP ≥ 10 mmHg to ≤ 40 mmHg, with an unchanged or increased cardiac output)
- ☐ Patient is hemodynamically unstable or has history of postural hypotension
- ☐ Patient has systemic hypotension (SBP ≤ 90 mmHg)
- ☐ Patient has depressed cardiac output (cardiac index ≤ 2.4 L/min/m²)
- ☐ Patient has known hypersensitivity
- ☐ Patient has documented bradycardia or second- or third-degree heart block
- ☐ Patient has signs of right-sided heart failure
- ☐ Other: _____

OR

☐ **The following CCB was trialed:**

CCB: _____

With the following response:

- ☐ Pulmonary arterial pressure continued to rise
- ☐ Disease continued to progress or patient remained symptomatic
- ☐ Patient hypersensitive or allergic
- ☐ Adverse event: _____
- ☐ Patient became hemodynamically unstable
- ☐ Other: _____

Prescriber signature: _____ **Date:** _____

Fax: 1-877-943-1000